iCAD Receives FDA Approval for FujiFilm Aspire HD Digital Mammography System

  iCAD Receives FDA Approval for FujiFilm Aspire HD Digital Mammography System

FDA Approval Provides Radiologists with Expanded Access to Next Generation CAD
                                   Platform

Business Wire

NASHUA, N.H. -- June 20, 2013

iCAD, Inc.  (NASDAQ: ICAD),  an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced approval by the U.S.
Food and Drug Administration (FDA) for use of the Company’s SecondLook^®
mammography computer-aided detection (CAD), on the next generation PowerLook
Advanced Mammography Platform (AMP)™, for FujiFilm’s Aspire™ HD Full-Field
Digital Mammography System.

“We are quite pleased to be able to expand our long standing partnership with
market leader FujiFilm to offer customers our next generation mammography
computer-aided detection platform, PowerLook Advanced Mammography Platform
with FujiFilm’s family of Aspire HD Full-Field Digital Mammography Systems,”
said Ken Ferry, CEO of iCAD. “This FDA approval further validates SecondLook
Digital CAD with PowerLook AMP as a leading tool in cancer detection allowing
us to deliver the most advanced and comprehensive imaging solutions to the
radiology community.”

PowerLook AMP provides radiologists with the ability to customize their CAD
solution to meet the needs of their individual work environment. The
technology expands on iCAD’s SecondLook Digital algorithm and is the CAD
platform upon which all future breast imaging CAD offerings from iCAD will be
built. SecondLook’s CAD metrics offer industry-leading tissue and lesion
characteristics to support the breast imager’s workflow. In addition,
PowerLook AMP is the first product of its kind to integrate Mātakina’s
Volpara^® Volumetric Breast Density assessment.

iCAD’s PowerLook AMP also provides the most powerful flexible DICOM
connectivity solution, enabling universal compatibility with leading PACS and
Review Workstations. Additional modules are expected to be released and
integrated into PowerLook AMP in the future.

About iCAD, Inc.

iCAD is an industry-leading provider of Computer-Aided Detection (CAD)
technologies, advanced image analysis, workflow solutions and radiation
therapies for the early identification and treatment of common cancers. iCAD
offers a comprehensive range of high-performance, upgradeable CAD solutions
for mammography and advanced image analysis and workflow solutions for
Magnetic Resonance Imaging, for breast and prostate cancers and Computed
Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation
treatment for early-stage breast cancer that can be administered in the form
of intraoperative radiation therapy or accelerated partial breast irradiation.
The Xoft System is also cleared for the treatment of non-melanoma skin cancer
and endometrial cancer. For more information, call (877) iCADnow, or visit
www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the risks relating
to the Company’s acquisition of Xoft including, the expected benefits of the
acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”,
“anticipate”, “likely”, and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the statement was
made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in
our public filings with the Securities and Exchange Commission, available on
the Investors section of our website at http://www.icadmed.com and on the
SEC’s website at http://www.sec.gov.

Contact:

For iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
For iCAD investor relations
LHA
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For iCAD media inquiries
Schwartz MSL
Helen Shik, 781-684-0770
iCAD@schwartzmsl.com
 
Press spacebar to pause and continue. Press esc to stop.